A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies

Matthew A. Gubens, Matthew Burns, Susan M. Perkins, Melanie San Pedro-Salcedo, Sandy K. Althouse, Patrick J. Loehrer, Heather A. Wakelee

Research output: Contribution to journalArticle

19 Scopus citations

Fingerprint Dive into the research topics of 'A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences